524 related articles for article (PubMed ID: 15509500)
1. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype.
Yoshimura M; Sakamoto M; Ikemoto M; Mochizuki Y; Yuasa K; Miyagoe-Suzuki Y; Takeda S
Mol Ther; 2004 Nov; 10(5):821-8. PubMed ID: 15509500
[TBL] [Abstract][Full Text] [Related]
2. [Current status and perspective of gene therapy on dystrophic animal model].
Takeda S
Rinsho Shinkeigaku; 2004 Nov; 44(11):911-3. PubMed ID: 15651329
[TBL] [Abstract][Full Text] [Related]
3. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
Athanasopoulos T; Graham IR; Foster H; Dickson G
Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965
[TBL] [Abstract][Full Text] [Related]
4. Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog.
Koo T; Okada T; Athanasopoulos T; Foster H; Takeda S; Dickson G
J Gene Med; 2011 Sep; 13(9):497-506. PubMed ID: 22144143
[TBL] [Abstract][Full Text] [Related]
5. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
Yuasa K; Sakamoto M; Miyagoe-Suzuki Y; Tanouchi A; Yamamoto H; Li J; Chamberlain JS; Xiao X; Takeda S
Gene Ther; 2002 Dec; 9(23):1576-88. PubMed ID: 12424610
[TBL] [Abstract][Full Text] [Related]
6. [Adeno-associated virus vector carrying human minidystrophin gene SMCKA3999 effectively ameliorates dystrophic pathology in mdx model mice].
Li HH; Zhang SM; Fang SY; Chen CL; Luo YD; Guan Y; Wang DW; Xiao X
Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(17):1513-6. PubMed ID: 14521733
[TBL] [Abstract][Full Text] [Related]
7. A canine minidystrophin is functional and therapeutic in mdx mice.
Wang B; Li J; Qiao C; Chen C; Hu P; Zhu X; Zhou L; Bogan J; Kornegay J; Xiao X
Gene Ther; 2008 Aug; 15(15):1099-106. PubMed ID: 18432277
[TBL] [Abstract][Full Text] [Related]
8. Enhanced effect of microdystrophin gene transfection by HSV-VP22 mediated intercellular protein transport.
Xiong F; Xiao S; Yu M; Li W; Zheng H; Shang Y; Peng F; Zhao C; Zhou W; Chen H; Fang L; Chamberlain JS; Zhang C
BMC Neurosci; 2007 Jul; 8():50. PubMed ID: 17617925
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery.
Abmayr S; Gregorevic P; Allen JM; Chamberlain JS
Mol Ther; 2005 Sep; 12(3):441-50. PubMed ID: 16099410
[TBL] [Abstract][Full Text] [Related]
10. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene.
Sakamoto M; Yuasa K; Yoshimura M; Yokota T; Ikemoto T; Suzuki M; Dickson G; Miyagoe-Suzuki Y; Takeda S
Biochem Biophys Res Commun; 2002 May; 293(4):1265-72. PubMed ID: 12054513
[TBL] [Abstract][Full Text] [Related]
11. Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy.
Gardner KL; Kearney JA; Edwards JD; Rafael-Fortney JA
Gene Ther; 2006 May; 13(9):744-51. PubMed ID: 16307000
[TBL] [Abstract][Full Text] [Related]
12. Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy.
Athanasopoulos T; Foster H; Foster K; Dickson G
Methods Mol Biol; 2011; 709():21-37. PubMed ID: 21194019
[TBL] [Abstract][Full Text] [Related]
13. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.
Yuasa K; Yoshimura M; Urasawa N; Ohshima S; Howell JM; Nakamura A; Hijikata T; Miyagoe-Suzuki Y; Takeda S
Gene Ther; 2007 Sep; 14(17):1249-60. PubMed ID: 17581597
[TBL] [Abstract][Full Text] [Related]
14. Efficient and fast functional screening of microdystrophin constructs in vivo and in vitro for therapy of duchenne muscular dystrophy.
Jørgensen LH; Larochelle N; Orlopp K; Dunant P; Dudley RW; Stucka R; Thirion C; Walter MC; Laval SH; Lochmüller H
Hum Gene Ther; 2009 Jun; 20(6):641-50. PubMed ID: 19239382
[TBL] [Abstract][Full Text] [Related]
15. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.
Li S; Kimura E; Ng R; Fall BM; Meuse L; Reyes M; Faulkner JA; Chamberlain JS
Hum Mol Genet; 2006 May; 15(10):1610-22. PubMed ID: 16595609
[TBL] [Abstract][Full Text] [Related]
16. [Gene therapy for muscular dystrophy].
Takeda S
No To Hattatsu; 2004 Mar; 36(2):117-23. PubMed ID: 15031985
[TBL] [Abstract][Full Text] [Related]
17. Full-length dystrophin gene transfer to the mdx mouse in utero.
Reay DP; Bilbao R; Koppanati BM; Cai L; O'Day TL; Jiang Z; Zheng H; Watchko JF; Clemens PR
Gene Ther; 2008 Apr; 15(7):531-6. PubMed ID: 18273052
[TBL] [Abstract][Full Text] [Related]
18. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart.
Yue Y; Li Z; Harper SQ; Davisson RL; Chamberlain JS; Duan D
Circulation; 2003 Sep; 108(13):1626-32. PubMed ID: 12952841
[TBL] [Abstract][Full Text] [Related]
19. Construction and analysis of compact muscle-specific promoters for AAV vectors.
Wang B; Li J; Fu FH; Chen C; Zhu X; Zhou L; Jiang X; Xiao X
Gene Ther; 2008 Nov; 15(22):1489-99. PubMed ID: 18563184
[TBL] [Abstract][Full Text] [Related]
20. [Construction of recombinant plasmid pVAX1-microdystrophin and preliminary study on the treatment to Duchenne muscular dystrophy].
Xiong F; Zhang C; Zheng H; Xiao S; Yu M; Xu Y; Liu Z; Zhou C
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):624-8. PubMed ID: 19065517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
